PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

Chinolons vs anybiotios, remarks on sensitivity of ehosen bacteria strains isolated from urine
Article published in Urologia Polska 1993/46/1.

authors

Janina Ruczkowska, Izabela Dolna, Ewa Mróz, Marta Chomontowicz
Z Katedry i Zakładu Mikrobiologii Lekarskiej AM we Wrocławiu Kierownik: prof. dr hab. med. K. Grzybek-Hryncewicz

summary

In vilro activity of ofloxacin (OFX), pefloxacin (PEF), nalidixic acid, nitrofurantoin and 14 antibiotics against 500 bacterial strains isolated from urine of hispitalized patients was compared. OFX and PEF proved to be the most active drugs against over 90% of isolated Staphylococci, E. coli, Klebsiella and Proteus mirabilis; less sensitive to OFX and PEF were Enterobacter (84,8%; 69,7%) and Proteus spp. (77,3%; 70,5%); the least nonfermentative Gram--negative rods (53,8%; 35,9%) and Pseudomonas aeruginosa (45,9%; 17,1%). Nalidixic acid was active against 33,3%-87,7% of the Gram-negative bacteria.
In general, OFX and PEF susceptibility of Gram-negative rods was similar to that of netilmicin, amikacin, cefotaxime and ceftriaxone, whereas susceptibility of Staphylococci to OFX and PEF similar to that of nitrofurantoin and a little bit higher than that of netilmicin and amikacin.

references

  1. 1. Auckenthaler R., Michea-Hamzehpour M., Pechere J.C.: In vitro activity of newer ±uinolones against aerobic bacteria. J. Antimicrob. Chemother. 1986, 17, Suppl. B, 29. —
  2. 2. Bauer A.W., Kirby W.M., Sherris J.C., Turck M.\\\\ Antibiotic susceptibility testing by a standardised single disc method. Am. J. Clin. Pathol., 1966, 45, 493. —
  3. 3. Bergogne--Berezin E.: Pefloxacin. Intern. J. Antimicrob. Agents, 1991, 1, 29. —
  4. 4. Boerema J.B.J., Pauwels R., Scheepers J., Crombach W.: Efficacy and safety of pefloxacin in the treatment of patients with complicated urinary tract infections. J. Antimicrob. Chemother., 1986, 17, Suppl. B, 103. —
  5. 5. Kromann-Andersen B., Sommer P., Pers C, Larsen V., Rasmussen F.: Ofloxacin compared with ciprofloxacin in the treatment of complicated lower urinary tract infections. J. Antimicrob. Chemother., 1988, 22, Suppl. C, 143. —
  6. 6. Michea-Hamzehpour M., Lucain C, Pechere J.\\\\ Resistance to pefloxacin in Pseudomonas aeruginosa. Antimicrob. Agents. Chemother., 1991, 35, 512. —
  7. 7. Moniot-Ville N., Guibert J., Moreau N., Acar J.F., Collatz E., Gutmann L.: Mechanism of ±uinolone resistance in a clinical isolate of Escherichia coli highly resistant to fluoro±uinolones but susceptible to nalidixic acid. Antimicrob. Agents Chemother., 1991, 35, 519. —
  8. 8. Neu H.C.: New strategies for the 1990\\\'S: antibacterial therapy. Intern. J. Antimicrob. Agents, 1991, 1, 47. —
  9. 9. Ruczkowska J., Dolna I.: Wrażliwo¶ć na ofloksacynę i inne chemioterapeutyki szczepów bakteryjnych izolowanych z moczu. Urol. Pol., 1990, 43, 181. —
  10. 10. Truckis M., Hooper D.C. Wolfson J.S.: Emerging resistance to fluorochinolones in staphylococci: an alert. Ann. Intern. Med., 1991, 114, 424.

correspondence

prof. dr hab. med. J. Ruczkowska
Ul. Chałubińskiego 4,
50-368 Wrocław